IN2015DN03921A - - Google Patents
Info
- Publication number
- IN2015DN03921A IN2015DN03921A IN3921DEN2015A IN2015DN03921A IN 2015DN03921 A IN2015DN03921 A IN 2015DN03921A IN 3921DEN2015 A IN3921DEN2015 A IN 3921DEN2015A IN 2015DN03921 A IN2015DN03921 A IN 2015DN03921A
- Authority
- IN
- India
- Prior art keywords
- release pharmaceutical
- pharmaceutical formulations
- formulations
- oprozomib
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/066679 WO2014066681A1 (fr) | 2012-10-24 | 2013-10-24 | Formulations à libération modifiée pour l'oprozomib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03921A true IN2015DN03921A (fr) | 2015-10-02 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3921DEN2015 IN2015DN03921A (fr) | 2012-10-24 | 2013-10-24 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (fr) |
| EP (1) | EP2912025A4 (fr) |
| JP (1) | JP6505604B2 (fr) |
| KR (1) | KR20150070406A (fr) |
| CN (1) | CN104968650A (fr) |
| AP (1) | AP3681A (fr) |
| AR (1) | AR093126A1 (fr) |
| AU (1) | AU2013334258A1 (fr) |
| BR (1) | BR112015008572A2 (fr) |
| CA (1) | CA2888039A1 (fr) |
| CL (1) | CL2015001085A1 (fr) |
| CR (1) | CR20150266A (fr) |
| EA (1) | EA201590797A1 (fr) |
| HK (2) | HK1208222A1 (fr) |
| IL (1) | IL238244A0 (fr) |
| IN (1) | IN2015DN03921A (fr) |
| MX (1) | MX2015005069A (fr) |
| PE (1) | PE20151051A1 (fr) |
| PH (1) | PH12015500823A1 (fr) |
| SG (1) | SG11201502849XA (fr) |
| TN (1) | TN2015000135A1 (fr) |
| TW (1) | TW201422255A (fr) |
| UY (1) | UY35091A (fr) |
| WO (1) | WO2014066681A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| CA2988918A1 (fr) | 2015-06-19 | 2016-12-22 | Biotie Therapies, Inc. | Formulations de tozadenant a liberation controlee |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| KR102524751B1 (ko) * | 2016-06-29 | 2023-04-21 | 케자르 라이프 사이언스 | 펩티드 에폭시케톤 면역프로테아제 저해제 및 그 전구체의 제조 방법 |
| WO2018057453A1 (fr) | 2016-09-21 | 2018-03-29 | Amgen Inc. | Formules à libération immédiate pour oprozomib |
| WO2018112078A1 (fr) | 2016-12-14 | 2018-06-21 | Amgen Inc. | Formes pharmaceutiques à libération modifiée et à rétention gastrique pour oprozomib et leur procédé de fabrication |
| WO2019053611A1 (fr) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Polythérapie pour le traitement du cancer |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| WO2023220641A2 (fr) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| US6673838B2 (en) * | 2001-02-12 | 2004-01-06 | Wyeth | Succinate salt of O-desmethyl-venlafaxine |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| PT2623113T (pt) * | 2005-11-09 | 2017-07-14 | Onyx Therapeutics Inc | Compostos para inibição de enzimas |
| US20100172988A1 (en) * | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| WO2008140782A2 (fr) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Composés d'inhibition enzymatique |
| TWI501773B (zh) * | 2007-10-04 | 2015-10-01 | Onyx Therapeutics Inc | 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成 |
| AR075899A1 (es) * | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
-
2013
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/fr not_active Abandoned
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Application Discontinuation
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/fr active Application Filing
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/fr not_active Withdrawn
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
- 2015-09-10 HK HK15108858.7A patent/HK1208222A1/xx unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
- 2016-03-31 HK HK16103699.0A patent/HK1215709A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215709A1 (zh) | 2016-09-09 |
| IL238244A0 (en) | 2015-06-30 |
| EP2912025A4 (fr) | 2016-06-08 |
| AP3681A (en) | 2016-04-19 |
| UY35091A (es) | 2014-05-30 |
| JP2015535255A (ja) | 2015-12-10 |
| HK1208222A1 (en) | 2016-02-26 |
| SG11201502849XA (en) | 2015-05-28 |
| JP6505604B2 (ja) | 2019-04-24 |
| TW201422255A (zh) | 2014-06-16 |
| EA201590797A1 (ru) | 2016-02-29 |
| AP2015008387A0 (en) | 2015-04-30 |
| BR112015008572A2 (pt) | 2017-07-04 |
| AU2013334258A1 (en) | 2015-04-30 |
| TN2015000135A1 (en) | 2016-10-03 |
| WO2014066681A1 (fr) | 2014-05-01 |
| US20160213610A1 (en) | 2016-07-28 |
| CN104968650A (zh) | 2015-10-07 |
| EP2912025A1 (fr) | 2015-09-02 |
| CR20150266A (es) | 2015-08-14 |
| PH12015500823A1 (en) | 2015-06-22 |
| KR20150070406A (ko) | 2015-06-24 |
| US9295708B2 (en) | 2016-03-29 |
| PE20151051A1 (es) | 2015-08-03 |
| MX2015005069A (es) | 2015-07-17 |
| AR093126A1 (es) | 2015-05-20 |
| US20140113855A1 (en) | 2014-04-24 |
| CA2888039A1 (fr) | 2014-05-01 |
| CL2015001085A1 (es) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| IN2012DN06720A (fr) | ||
| EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
| MX354210B (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| MY165149A (en) | Use of binders for manufacturing storage stable formulations | |
| HK1218884A1 (zh) | 用於在口腔中釋放至少種活性藥物成分的固體藥物劑型 | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| MX340188B (es) | Elaboracion de granulos sin activos y tabletas que comprenden los mismos. | |
| MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
| PT3003383T (pt) | Composição sólida para administração oral que contém ácido ibandrónico ou um seu sal farmaceuticamente aceitável e vitamina d | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| PH12016502540A1 (en) | Pharmaceutical dosage forms | |
| ZA201500411B (en) | Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process | |
| EA201491477A1 (ru) | Фармацевтические составы, содержащие флупиртин | |
| MY159675A (en) | Clerodane derivatives for modulation of leukotriene receptor activity and related diseases | |
| MX2015013279A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| IN2015MU00907A (fr) | ||
| WO2014064711A3 (fr) | Procédés d'administration de raltégravir et de compositions de raltégravir | |
| ES2422657A1 (es) | Composición farmacéutica sólida de cilostazol | |
| TH132242B (th) | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยไฮโดรมอร์โฟนและนาล็อกโซน (Pharmaceutical compositions comprising hydromorphone and naloxone) | |
| TR201901677T4 (tr) | Sitidin analoglarının oral formülasyonları ve bunların kullanım yöntemleri. | |
| TN2011000018A1 (en) | Pharmaceutical formulations containing dopamine receptor ligands |